Article Details

GSK licenses Shigella vaccine candidate to Bharat Biotech for continued development

Retrieved on: 2025-06-12 08:33:22

Tags for this article:

Click the tags to see associated articles and topics

GSK licenses Shigella vaccine candidate to Bharat Biotech for continued development. View article details on hiswai:

Excerpt

... immune system. GMMA technology is low-cost and scalable, making it ideal for producing affordable vaccines for low-income countries, while ...

Article found on: www.gsk.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo